Targeting Cdc20 as a novel cancer therapeutic strategy.
Targeting Cdc20 as a novel cancer therapeutic strategy.
复制标题
DOI:
10.1016/j.pharmthera.2015.04.002
复制
发表时间:
2015-07
影响因子:
13.5
通讯作者:
Wei, Wenyi
中科院分区:
文献类型:
--
作者:
Wang, Lixia;Zhang, Jinfang;Wan, Lixin;Zhou, Xiuxia;Wang, Zhiwei;Wei, Wenyi
The Anaphase Promoting Complex (APC, also called APC/C) regulates cell cycle progression by forming two closely related, but functionally distinct E3 ubiquitin ligase sub-complexes, APCCdc20 and APCCdh1, respectively. Emerging evidence has begun to reveal that Cdc20 and Cdh1 have opposing functions in tumorigenesis. Specifically, Cdh1 functions largely as a tumor suppressor, whereas Cdc20 exhibits an oncogenic function, suggesting that Cdc20 could be a promising therapeutic target for combating human cancer. However, the exact underlying molecular mechanisms accounting for their differences in tumorigenesis remain largely unknown. Therefore, in this review, we summarize the downstream substrates of Cdc20 and the critical functions of Cdc20 in cell cycle progression, apoptosis, ciliary disassembly and brain development. Moreover, we briefly describe the upstream regulators of Cdc20 and the oncogenic role of Cdc20 in a variety of human malignancies. Furthermore, we summarize multiple pharmacological Cdc20 inhibitors including TAME and Apcin, and their potential clinical benefits. Taken together, development of specific Cdc20 inhibitors could be a novel strategy for the treatment of human cancers with elevated Cdc20 expression.
登录
查看更多内容
DOI:
10.1083/jcb.201211019
发表时间:
2013-06-24
期刊:
The Journal of cell biology
影响因子:
--
作者:
Clijsters L;Ogink J;Wolthuis R
通讯作者:
Wolthuis R
DOI:
10.1016/j.bbamcr.2013.02.028
发表时间:
2014-01
影响因子:
5.1
作者:
Bassermann, Florian;Eichner, Ruth;Pagano, Michele
通讯作者:
Pagano, Michele
影响因子:
11.4
作者:
Akiyama, T;Bouillet, P;Tanaka, S
通讯作者:
Tanaka, S
影响因子:
5.3
作者:
Castro, A;Vigneron, S;Lorca, T
通讯作者:
Lorca, T
影响因子:
64.8
作者:
Bashir, T;Dorrello, NV;Pagano, M
通讯作者:
Pagano, M